Use of positron emission tomography with [18F]-FDG in oncology: Results in urological cancers;Résultats dans les cancers urologiques

Bulletin du Cancer

Volumn 90, Issue 2 SPEC. ISS., 2003, Pages

  Bourguet, Patrick ^a   Blanc Vincent, Marie Pierre ^b   Boneu, Andrée ^c   Bosquet, Lise ^b   Chauffert, Bruno ^d   Corone, Carine ^e   Courbon, Frédéric ^c   Devillers, Anne ^a   Foehrenbach, Hervé ^f   Lumbroso, Jean Daniel ^g   Mazselin, Philippe ^f   Motravers, Françoise ^h   Moretti, Jean Luc ⁱ   Talbot, Jean Noël ^h   Avril, Marie Françoise ^g   Banal, Main ^e   Bey Boeglin, Martine ^j   Bonichon, Françoise ^k   Bugat, Rolland ^c   Bui Nguyen, Binh ^k   Cherel, Pascal ^e   Chevreau, Christine ^c   Fervers, Béatrice ^b   Floiras, Jean Louis ^e   Fournier, Robert ^l   Goldwasser, François ^m   Goupil, Alain ^e   Grahek, Dany ^h   Guillo, Sylvie ^b   Helal, Ourkia ⁿ   Houlgatte, Alain ^f   Lacau St Guily, Jean ^h   Lamy De La Chapelle, Thierry ^o   Pecking, Alain ^e   Périé, Sophie ^h   Reboul, François ^p   Théodore, Christine ^g   Tilly, Hervé ^q   Vaylet, Fabien ^r   Véra, Pierre ^q   Bataillard, A ^b   Bey, P ^s   Borges Paninho, H ^b   Brusco, S ^b   Carretier, J ^b   Debuiche, S ^b   Delavigne, V ^b   Esteves E ^b   Fabre, N ^b   Farsi, F ^t   Gory Delabaere, G ^b   Guy, A G ^b   Haugh, M ^b   Laforet C ^b   Leichtnam, L ^b   Luporsi, E ^u   Philip, T ^t   Renaud Salis, J L ^k   Rope D ^b   Theobald, S ^v   more..

^a CENTRE EUGÈNE MARQUIS   (France)

^b FNCLCC   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f University of Paris Descartes   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL TENON   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j Cabinet du Docteur Fargeon   (France)

^k Intitut Bergonie   (France)

^l Military Teaching Hospital Sainte Anne   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ HÔPITAL ANTOINE BÉCLÈRE   (France)

^o PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^p INSTITUT SAINTE CATHERINE   (France)

^q CENTRE HENRI BECQUEREL   (France)

^r PERCY MILITARY HOSPITAL   (France)

^s INSTITUT CURIE   (France)

^t CENTRE LÉON BÉRARD   (France)

^u CENTRE ALEXIS VAUTRIN   (France)

^v CENTRE PAUL STRAUSS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; METASTASIS; NEPHRECTOMY; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; TESTIS CANCER; URINARY TRACT CANCER;

BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SEMINOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 17544402359     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. 18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 1991; 146: 1470-4.
2. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Die Positronenemissionstomographie zur Diagnostik des Nierenzellkarzinoms. Urologe A 1996; 35: 146-50.
3. Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510-5.
4. Montravers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nuclear Med 2000; 41: 78-84.
5. Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-30.
6. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 1997; 17: 1655-60.
7. Hoh CK, Seltzer MA, Franklin J, de Kernion JB, Phelps ME, Belldegrun. Positron emission tomography in urological oncology. J Urol 1998; 159: 347-56.
8. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-6.
9. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 1998; 58: 3009-14.
10. Wang GJ, Volkow ND, Wolf AP, Madajewicz S, Fowler JS, Schlyer DJ, et al. Positron emission tomography study of human prostatic adenocarcinoma using carbon-11 putrescine. Nuclear Med Biol 1994; 21: 77-82.
11. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nuclear Med Biol 1996; 23: 693-7.
12. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31-5.
13. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jap J Clin Oncol 1999; 29: 623-9.
14. Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez R, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU International 1999; 84: 1028-31.
15. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancet. J Urol 1999; 162: 1322-8.
16. Heicappell R, Mullet-Manheis V, Reinhardt M, Vosberg H, Gerharz CD, Muller-Gartner H, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 1999; 36: 582-7.
17. Kanamaru H, Oyama N, Akino H, Okada K. Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 2000; 46: 851-3.
18. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-11.
19. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nuclear Med Communication 2001; 22: 963-9.
20. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart, et al. Fluorodeoxyglucose PET in the initial staging of germ cell rumours. Eur J Nuclear Med 2000; 27: 590-4.
21. Kosuda S, Fisher S, Kison PV, Wahl RL, Grossman HB. Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nuclear Med 1997; 11: 195-9.
22. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999; 53: 808-11.
23. Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nuclear Med 1998; 39: 815-22.
24. Cremerius U, Wildberger JE, Botchers H, Zimny M, Jakse G, Gunther RW, et al. Does positron emission tomography using 18-fluoro-2deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999; 54: 900-4.
25. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teraroma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999; 211: 249-56.
26. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14: 1637-41.
27. Nuutinen JM, Leskinen S, Elomaa I, Minn H, Varpula M, Solin O, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33: 1234-41.
28. Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A. Tomographie a émission de positons (T.E.P.) au fluorodéoxyglucose (F.D.G.) dans les tumeurs germinales testiculaires de l'adulte: première évaluation clinique française, mise au point sur la technique et ses applications cliniques. Progrès en Urologie 2000; 10: 1190-9.
29. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-4.
30. Rayson D, Burch PA, Richardson RL. Sarcoidosis and testicular carcinoma. Cancer 1998; 83: 337-43.
31. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991; 67: 1544-50.
32. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nuclear Med 1997; 24: 615-20.
33. Bachor R, Kotzerke J, Reske SN, Hautmann R. Das Lymphknotenstaging des Harnblasenkarzinoms mit det Positronenemissionstomographie. Urologe A 1999; 38: 46-50.
34. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiologica 1996; 37: 180-5.
35. Harney JV, Wahl RL, Liebett M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy, 2-(18F) fluoto-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991; 145: 279-83.